financetom
Business
financetom
/
Business
/
CH Robinson Worldwide Offers Runway for Margin Expansion, EPS Growth, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CH Robinson Worldwide Offers Runway for Margin Expansion, EPS Growth, UBS Says
Oct 5, 2024 5:13 AM

12:51 PM EDT, 10/04/2024 (MT Newswires) -- CH Robinson Worldwide's ( CHRW ) operational improvement initiatives will boost earnings per share and increase the stock price, UBS said in a note Friday.

"Our 2025 EPS forecast is 12% ahead of consensus, as we expect CHRW to continue using technology tools to support gross

margin expansion, and productivity programs to drive progress toward a 40% operating margin in its NAST business," UBS analysts, including Thomas Wadewitz, said. NATS refers to North American Surface Transportation.

While a stronger truckload market would provide a clear tailwind, the analysts expect margin progress in 2025, and model a 37.5% margin even with only modest improvement in the cycle.

"We expect upside to 3Q EPS and CHRW's December 12 analyst meeting to act as catalysts for the stock," the analysts said. They raised their Q3 EPS estimate to $1.32, up from $1.24, and 2025 estimate to $5.25 from $4.75.

UBS upgraded CH Robinson Worldwide ( CHRW ) to buy from neutral and raised its price target to $140 from $100.

Price: 105.70, Change: +0.19, Percent Change: +0.18

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
DallasNews Files Proxy Statement for Proposed Buyout by Hearst
DallasNews Files Proxy Statement for Proposed Buyout by Hearst
Aug 18, 2025
08:03 AM EDT, 08/18/2025 (MT Newswires) -- DallasNews ( DALN ) said Monday it has filed a definitive proxy statement for its proposed acquisition by Hearst. Under Hearst's proposal, DallasNews ( DALN ) shareholders will receive $15 per share in cash, implying a premium of 242% over the company's last class A share price close of $4.39 before the proposal...
Sunrun Likely to Offer Longer-Term Demand Visibility Due to US Treasury Guidance, RBC Says
Sunrun Likely to Offer Longer-Term Demand Visibility Due to US Treasury Guidance, RBC Says
Aug 18, 2025
08:01 AM EDT, 08/18/2025 (MT Newswires) -- Sunrun ( RUN ) is likely to offer longer-term demand visibility due to the US Treasury outlook, which will also help the company largely eliminate the uncertainty under President Trump's executive order for stringent Treasury guidance on enforcement of commerce construction rules, RBC said in a Monday note. The company's value proposition lies...
Soligenix Says Dusquetide Gets Orphan Drug Designation From US FDA to Treat Behcet's Disease
Soligenix Says Dusquetide Gets Orphan Drug Designation From US FDA to Treat Behcet's Disease
Aug 18, 2025
08:04 AM EDT, 08/18/2025 (MT Newswires) -- Soligenix ( SNGX ) said Monday that the US Food and Drug Administration has granted orphan drug designation to dusquetide for the treatment of Behcet's disease, an inflammatory disorder of the blood vessels. The decision was made after a review of the recent phase 2a clinical results showing biological efficacy and safety in...
Aptose Biosciences Reports Early Positive Tuspetinib Safety Data Across Newly Diagnosed AML Patients
Aptose Biosciences Reports Early Positive Tuspetinib Safety Data Across Newly Diagnosed AML Patients
Aug 18, 2025
08:01 AM EDT, 08/18/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) on Monday said the latest data update from the Phase 1/2 Tuscany trial in newly diagnosed acute myeloid leukemia (AML) patients show no significant safety concerns with different dose levels of the company's lead candidate, tuspetinib. The trial was initiated last December. Data from 10 patients across all...
Copyright 2023-2026 - www.financetom.com All Rights Reserved